Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs EZETIMIBE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Inhibits Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing intestinal absorption of dietary and biliary cholesterol, leading to decreased hepatic cholesterol stores and increased clearance of cholesterol from the blood.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Adjunctive therapy to diet for reduction of elevated total cholesterol, LDL-C, and apolipoprotein B in patients with primary hyperlipidemia (heterozygous familial and non-familial),Homozygous familial hypercholesterolemia (Ho FH) in combination with other lipid-lowering treatments,Homozygous sitosterolemia (phytosterolemia),Mixed hyperlipidemia (in combination with fenofibrate),Prevention of cardiovascular events in patients with coronary heart disease (in combination with simvastatin, off-label use),Reduction of residual cardiovascular risk in patients with a history of acute coronary syndrome (off-label use)
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
10 mg orally once daily, with or without food, at any time of day.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Approximately 22 hours for ezetimibe and its active glucuronide metabolite; steady-state achieved within 3-7 days.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily metabolized via glucuronidation by UGT1A1, UGT1A3, and UGT2B15; minimal CYP450 involvement (negligible oxidative metabolism). Ezetimibe and ezetimibe-glucuronide undergo enterohepatic recycling. Elimination is via biliary and fecal routes; renal excretion is minimal.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Biliary and fecal: ~78% as parent compound; renal: ~11% as metabolite; enterohepatic recirculation occurs.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
>99.7% bound to human plasma proteins, primarily albumin.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Not applicable; ezetimibe has a Vd of approximately 18 L/kg due to extensive tissue distribution, but clinical relevance is limited.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Oral: variable; estimated ~35-65% due to extensive glucuronidation and enterohepatic recycling.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment required for any degree of renal impairment including end-stage renal disease.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Contraindicated in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment. Use with caution in mild hepatic impairment without clear dose recommendations.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Children ≥10 years: 10 mg orally once daily. Children <10 years: safety and efficacy not established; use not recommended.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No specific dose adjustment needed. Use standard adult dosing based on clinical studies including patients >65 years.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
None.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hepatic impairment: Not recommended in moderate to severe liver dysfunction; monitor liver enzymes when coadministered with statins or fenofibrate.,Myopathy/Rhabdomyolysis: Increased risk when used with statins, especially at higher doses; caution in patients with predisposing factors (e.g., renal impairment, hypothyroidism).,Pancreatitis: Rare cases reported, especially with concomitant fenofibrate.,Cholelithiasis: May increase cholesterol secretion into bile, potentially causing gallstones; use caution in patients with biliary obstruction.,Hypersensitivity: Monitor for allergic reactions (e.g., angioedema, rash, urticaria).,Fetal risk: Use only if clearly needed in pregnancy (Category C); discontinue nursing or drug in lactating women.,Pediatric use: Safety and efficacy established in adolescents (≥10 years) for Ho FH and sitosterolemia; not recommended for primary hyperlipidemia in pediatric patients <10 years.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Hypersensitivity to ezetimibe or any component of the formulation.,Active liver disease or unexplained persistent elevations in serum transaminases (when used with a statin).,Coadministration with a statin in pregnant or nursing women (relative contraindication).
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
No significant food interactions. Avoid high-fat meals if combined with statins (to minimize statin-related myopathy risk). Bile acid sequestrants (e.g., cholestyramine) should be taken at least 4 hours before or 2 hours after ezetimibe to reduce absorption interference.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. FDA Pregnancy Category C. No known risk of congenital anomalies based on limited data, but cannot exclude risk; avoid use in first trimester unless clearly needed.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Unknown if excreted in human breast milk; no data on M/P ratio. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug, considering importance of drug to mother.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
No pharmacokinetic data indicate need for dose adjustment during pregnancy; use same dose as non-pregnant adults if clinically indicated.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Ezetimibe inhibits intestinal absorption of cholesterol via the Niemann-Pick C1-like 1 (NPC1L1) protein. It is often used as adjunctive therapy to statins for LDL-C lowering. Unlike statins, it does not affect hepatic HMG-Co A reductase and has minimal drug interactions, making it useful for statin-intolerant patients. It can be combined with fenofibrate but caution with gemfibrozil due to increased risk of cholelithiasis. Contraindicated in active liver disease or unexplained persistent transaminase elevations. No dose adjustment needed in chronic kidney disease.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Take ezetimibe exactly as prescribed, usually once daily with or without food.,It is usually taken in addition to a statin or other cholesterol-lowering medications.,You may experience mild side effects such as diarrhea, joint pain, or upper respiratory infection.,Rarely, serious muscle pain or liver problems can occur; report unexplained muscle aches, tenderness, or weakness, especially if accompanied by fever or dark urine.,Keep taking the medication even if you feel well, as high cholesterol has no symptoms.,Do not stop or change your dose without discussing with your doctor.,Inform your healthcare provider about all other medications, especially bile acid sequestrants (e.g., cholestyramine) which may reduce ezetimibe absorption.,Pregnancy and breastfeeding: Use only if clearly needed; discuss with your doctor.
No interactions on record
"Nicergoline, an ergot derivative with alpha-adrenergic blocking and vasodilatory properties, may enhance the cholesterol-lowering effects of ezetimibe by increasing its bioavailability through inhibition of intestinal P-glycoprotein (P-gp) and OATP1B1 transporters. This interaction can lead to elevated plasma concentrations of ezetimibe, potentially increasing the risk of adverse effects such as myopathy, rhabdomyolysis, and hepatotoxicity. Clinicians should monitor for signs of muscle pain or liver enzyme abnormalities when these drugs are coadministered."
"Lovastatin, a HMG-CoA reductase inhibitor, can increase the systemic exposure of ezetimibe, a cholesterol absorption inhibitor, via inhibition of OATP1B1 and possibly other transporters, leading to elevated ezetimibe-glucuronide concentrations. This interaction potentiates the lipid-lowering effect but may also increase the risk of ezetimibe-related adverse effects, such as myalgia or transaminase elevations, although clinical significance is generally low. The combination is often used intentionally for additive LDL-C reduction in patients requiring intensive lipid management."
"Coadministration of lisuride, a dopamine receptor agonist, and ezetimibe, a cholesterol absorption inhibitor, may theoretically increase the risk of adverse effects such as hypotension, syncope, and gastrointestinal disturbances. Lisuride can cause orthostatic hypotension and dizziness, and concomitant use with ezetimibe, which has been associated with rare cases of myopathy and hepatic enzyme elevations, may additively impair hemodynamic stability or hepatic function. Clinical vigilance is warranted as the combined pharmacological profiles could potentiate central nervous system depressant effects or unforeseen drug-drug interactions, especially in elderly patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs EZETIMIBE, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. EZETIMIBE is a Cholesterol Absorption Inhibitor that works by Inhibits Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing intestinal absorption of dietary and biliary cholesterol, leading to decreased hepatic cholesterol stores and increased clearance of cholesterol from the blood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and EZETIMIBE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of EZETIMIBE is: 10 mg orally once daily, with or without food, at any time of day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and EZETIMIBE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. EZETIMIBE is classified as Category A/B. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. FDA Pregnancy Category C. No known risk of congenital anomalies based on li. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.